Requirements for Insulin Glargine 300 U/Ml for Patients with Type-1 DiabetesMellitus Previously Treated with Insulin Glargine 100 U/Ml, According to theNumber of Daily Injections Given Previously

Aims: To assess the requirement for insulin glargine 300 U/mL (Gla-300) in people with Type 1 diabetes mellitus (Type 1 DM) previously treated with glargine 100 U/mL (Gla-100), depending on the prior number of daily injections of insulin. The secondary goal is to observe the differences in HbA1c and hypoglycaemia after 6 months of treatment with Gla-300. Methods: Cross-sectional observational study of people with type 1 DM treated with basal-bolus therapy. Group 1: participants treated with a single dose of insulin Gla-100. Group 2: participants treated with two doses a day. Following medical criteria, all subjects were switched to insulin Gla-300. Results: 133 participants with type 1 DM: 73 in Group 1 and 60 in Group 2. The participants in Group 2 required a significantly higher dose of basal insulin than those in Group 1, both on a baseline level and at 6 months. No differences in mealtime insulin were observed. There was a significantly increase in insulin dose of Gla-300 than previous doses of Gla-100 in both groups: 18.2% in Group 1 vs 6.4% in Group 2 (p < 0.001). No changes in HbA1c were observed in the two groups at 6 months of treatment and there was a significant reduction in hypoglycaemia in Group 1 (6 vs 4 per month). Conclusion: Group 2 participants needed a lower increase in their dose of insulin on switching to Gla-300 than subjects in Group 1. The subjects in Group 1 presented less hypoglycaemia after switching treatment, without changes in HbA1c levels.